DANBURY, Conn., May 13 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that the Company has been selected for inclusion in the NASDAQ Biotechnology Index (NBI), effective as of the market's open on Monday, May 19, 2008.
"We are pleased to be included in the NASDAQ Biotechnology Index and believe Biodel's inclusion is a result of the Company's consistent achievement of its goals," stated Dr. Solomon Steiner, Chairman and Chief Executive Officer of Biodel. "We look forward to reporting on future 2008 goals including the results from our two pivotal Phase III clinical trials for VIAject(TM) in September or October and the filing of our NDA submission for a suite of VIAject(TM) presentations by the end of 2008."
Launched in 1993, the NBI includes biotechnology and pharmaceutical companies listed on the NASDAQ National Market that meet minimum requirements for market value, average daily share volume and seasoning as a public company. The index is ranked on a semi-annual basis in May and November and serves as the basis for the iShares Nasdaq Biotechnology Index Fund (Amex: IBB). For more information about the Nasdaq Biotechnology Index, including eligibility criteria, visit http://www.nasdaq.com.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the
development and commercialization of innovative treatments for endocrine
disorders, such as diabetes and osteoporosis. Biodel's product candidates
are developed by using VIAdel(TM) technology, which reformulates existing
FDA- approved peptide drugs. The Company's lead product candidate,
VIAject(TM), is an ultra rapid-acting injectable meal-time insulin in
|SOURCE Biodel Inc.|
Copyright©2008 PR Newswire.
All rights reserved